Tritonix.ai

News / Korea / yonhap_finance

Shinhan Securities Raises Alteogen Target Price Following Novartis Mega-Deal

Health Technology · Biotechnology · yonhap_finance · 2026-09-02

196170

Shinhan Securities has increased its target price for Alteogen to 540,000 KRW, highlighting the strategic significance of its 4.4 trillion KRW Novartis deal.

What Happened

Landmark Novartis Agreement: Shinhan Securities has raised its target price for Alteogen to 540,000 KRW, following a massive licensing deal with Novartis worth up to 4.4 trillion KRW. The agreement is highly significant as it marks the world's first effort to convert an antibody-oligonucleotide conjugate (AOC) gene therapy into a subcutaneous (SC) formulation.

Expanding Technological Leadership: Alteogen continues to pioneer the SC delivery market, moving from ADC SC development to AOC gene therapy. This deal serves as a critical validation of their technology, likely influencing other global gene therapy firms to pursue similar SC conversion strategies.

Significant Revenue Potential: The contract covers up to 10 distinct products, with per-item upfront payments expected to exceed those of previous deals like the one with Biogen. If all 10 products are developed, the company could secure over 200 billion KRW in additional upfront payments.

Strong Growth Momentum: With a record-breaking 16 trillion KRW in cumulative licensing deals this year and successful patent defenses, Alteogen remains a top pick. The company is well-positioned for continued growth throughout the remainder of the year as it capitalizes on its proprietary SC technology.

Read original

More in Health Technology

Daewoong Pharmaceutical Shares Fall as Medytox Increases Damages Claim

Health Technology · yonhap_finance · 2026-09-03

Daewoong Pharmaceutical shares dropped early today after Medytox increased its damages claim to 500 billion KRW in their ongoing botulinum toxin dispute.

069620, 086900

Alteogen Shares Surge on $3.2 Billion Licensing Deal with Novartis

Health Technology · yonhap_finance · 2026-09-03

Alteogen's stock rose after announcing a major licensing agreement with Novartis for its proprietary subcutaneous injection technology platform, ALT-B4.

196170

Shinyoung Securities Slashes Binex Price Target Amid Growth Slowdown

Health Technology · yonhap_finance · 2026-09-02

Shinyoung Securities has significantly lowered its price target for Binex to 11,000 won, citing sluggish growth in the bio division and facility downtime.

053030

Latest in Korea

Kwangju Bank Partners with Credit Guarantee Foundation to Support Small Business Debt Refinancing

Finance · yonhap_finance · 2026-09-03

Kwangju Bank has signed an agreement with the Gwangju Credit Guarantee Foundation to help local small businesses consolidate debt and reduce financial burdens.

NY Fed President Williams: Rising Treasury Yields Reflect Economic Strength

Finance · yonhap_finance · 2026-09-03

New York Fed President John Williams stated that the recent surge in U.S. Treasury yields is a sign of a robust economy rather than market dysfunction.

Daishin Securities Launches Relay Seminar Series for H2 Investment Strategy

Finance · yonhap_finance · 2026-09-03

Daishin Securities will host a six-part seminar series through November, offering expert insights on market trends and sector-specific investment strategies.

003540

Corporate Bond Market Rebounds in September with Strong Demand

Finance · yonhap_finance · 2026-09-03

The corporate bond market has regained momentum in September, as companies like Coway and Hana Securities see massive oversubscription in recent offerings.

021240